I love pediatric benchmarks. Knowing the real underlying behavior in my clients' offices helps me speak to them and understand them better. There's a particular joy and insight to finding data that challenges the status quo understanding that physicians have of their own offices.
I get a lot of little messages every day that I feel like I should save and/or share, but they don't add up to an entire blog entry (I don't like to do more than one a day, if that, as it feels like spamming). So, here's my house cleaning:
In response to concerns raised by the AAP and several pediatricians across the country, UHC revised its clinical policy on palivizumab. Effective January 1, 2008, benefits coverage for palivizumab will now be aligned with the AAP recommendations published in the Red Book. UHC is in the process of sending notification letters to its physician provider network. A copy of the AAP letter to UHC can be accessed on the AAP Member Center, private payer advocacy page. Many thanks to SOAPM members for sharing information about the change.
Thanks to The Verden Group for that text.
Pricing up 4%, effective Mar 1, on Gardisil, MMR, Rotashield, Varivax
Gardisil promo (if you purchase >70 doses) extended until Feb 29
Time to negotiate with your inscos for an increase in reimbursement
before you have to buy in at the higher price